Consensus Contineum Therapeutics, Inc.

Equities

CTNM

US21217B1008

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
16.11 ^USD	+1.58%		+7.69%	0.00%

Apr. 30	Morgan Stanley Starts Contineum Therapeutics With Overweight Rating	MT
Apr. 30	Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target	MT

Evolution of the average Target Price on Contineum Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3eb5e2acd7b0759.zth2BBPV0dPYvhrBJ6-pJJ8nM0m7x3IPc7pIzV_2P7A.u48pPUGPt-fojyOIc-DbaMxgUgDogBpYIsIKtA-OXPeIqABWQoSLppbsaQ~d56236cf2468c9169b0c41b26ef38281

Analyst Recommendations on Contineum Therapeutics, Inc.

Morgan Stanley Starts Contineum Therapeutics With Overweight Rating	Apr. 30	MT
Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target	Apr. 30	MT
RBC Initiates Contineum Therapeutics at Outperform, Speculative Risk With $30 Price Target	Apr. 30	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.11 USD

Average target price

28 USD

Spread / Average Target

+73.81%

High Price Target

30 USD

Spread / Highest target

+86.22%

Low Price Target

25 USD

Spread / Lowest Target

+55.18%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Contineum Therapeutics, Inc.

RBC Capital Markets
Stifel Nicolaus
Morgan Stanley

Quarterly revenue - Rate of surprise

Company calendar